Summary of Study ST000220

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000050. The data can be accessed directly via it's Project DOI: 10.21228/M8RG6T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Show all samples  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000220
Study TitleSmall cell lung cancer metabolome (part II)
Study TypeComparison of normal, lung adenocarcinoma and SCLC tissue metabolomes
Study SummaryIn addition to the generation and analysis of metabolomics data on cell lines, samples of normal lung tissue, adenocarcinoma lung tissue and small cell lung carcinoma tissue (seven samples/group) were processed and evaluated metabolite profile differences under the scope of the pilot and feasibility study. These data can be correlated to the metabolite profiles defined in the SCLC and NSCLC cell lines and integrated with the ABPP-determined metabolic kinases to identify distinct metabolic signatures or biomarkers (?oncometabolites?) that distinguish small cell lung cancer from non-small cell lung cancer.
Institute
University of North Carolina
DepartmentSystems and Translational Sciences
LaboratorySumner Lab
Last NameSumner
First NameSusan
AddressEastern Regional Comprehensive Metabolomics Resource Core, UNC Nutrition Research Institute, 500 Laureate Way, Kannapolis, NC, 28081
Emailsusan_sumner @unc.edu
Phone704-250-5066
Submit Date2015-06-26
Num Groups3
Total Subjects21
Raw Data AvailableYes
Raw Data File Type(s)raw(Waters)
Uploaded File Size58 G
Analysis Type DetailLC-MS
Release Date2016-07-08
Release Version1
Susan Sumner Susan Sumner
https://dx.doi.org/10.21228/M8RG6T
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000050
Project DOI:doi: 10.21228/M8RG6T
Project Title:Small cell lung cancer metabolome
Project Type:Metabolomic profiling comparison between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), to define novel biomarkers for therapy, diagnostics and early detection.
Project Summary:The goal of this pilot project is to comprehensively evaluate metabolic underpinnings of small cell lung cancer (SCLC) and couple with proteome level measurements of global kinase and other enzyme level expression data to provide insight into the upstream signaling networks that may be driving the pathogenesis of SCLC. Alterations in cancer metabolism are increasingly realized as an emerging area of research and potentially offers new therapeutic strategies. As part of ongoing studies, we are employing a chemical biology platform, activity-based protein profiling (ABPP), to study the SCLC proteome. ABPP uses chemical probes that are directed against the active sites of enzymes to interrogate the functional state of enzymes in biological samples. We used ATP based probes to study differences in kinase and other ATP binding proteins between SCLC and non-small cell lung cancer (NSCLC). We used well curated lung cancer cell lines that facilitate functional analysis of key proteins and pathways. Interestingly, our preliminary data strongly implicates hyperactivated metabolic pathways in SCLC when compared to NSCLC cell lines. A strong signal of upregulated metabolic kinases and other proteins involved in glycolysis, pyruvate metabolism, and purine metabolism have been identified through this approach. However, whether the alterations in the protein levels identified through this proteomic based approach corresponds to altered levels of metabolites through metabolic pathways remains unclear. This new opportunity will allow us to profile SCLC for alterations in metabolism that can be compared to NSCLC. We will conduct metabolomics studies on our SCLC cell lines. Relationships between the underlying alterations in metabolic kinases and other signaling molecules and mechanisms promoting the aggressive phenotype of these SCLC tumors remain unclear. We will collaborate with the NIH Eastern Regional Comprehensive Metabolomics Resource Core at RTI International (RTI RCMRC) to enable metabolomic profiling and analysis of our existing cell lines and tumor tissues.
Institute:H. Lee Moffitt Cancer Center
Department:NCI-designated comprehensive cancer center
Last Name:Haura
First Name:Eric B.
Address:12902 Magnolia Drive, MRC 3 East
Email:eric.haura@moffitt.org
Phone:813-745-6827
  logo